Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
September 07, 2022 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2022 17:27 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...
Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
August 15, 2022 16:57 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 10, 2022 07:00 ET
|
Cullinan Oncology, Inc.
Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented updated Phase 1/2a data for CLN-081 at the 100mg BID dose showing...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2022 16:55 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...
Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference
August 01, 2022 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology to Participate in William Blair Biotech Focus Conference
July 05, 2022 16:01 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 16:37 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...
Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417
June 23, 2022 08:00 ET
|
Cullinan Oncology, Inc.
Cullinan Oncology receives upfront cash payment of $275 million, with potential to receive up to an additional $130 million in regulatory-based milestone payments Taiho obtains exclusive global...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2022 17:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...